December 15, 2011
FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym™ for Cushing's Syndrome

December 14, 2011
Amarin Announces the Addition of Industry Veteran Patrick O'Sullivan to Board

December 14, 2011
Blood-Based Gene Expression Test Beats MPI for Ruling Out Obstructive CAD

December 12, 2011
Aptus Endosystems Completes First HeliFX™ Procedures in US

December 7, 2011
'Smartphone glasses' are unlike anything you've seen Before

November 25, 2011
Amarin Announces FDA Acceptance for Filing of AMR101 NDA

November 22, 2011
Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters

November 22, 2011
NxStage Enhances Patient Awareness Efforts with Launch of Online Nephrologist Directory To Help Patients Connect with Local System One Prescribers

November 21, 2011
Amarin Added to NASDAQ Biotechnology Index

November 21, 2011
Aptus Receives FDA Clearance for HeliFX™ System

November 15, 2011
CardioDx Blood-Based Gene Expression Test Demonstrates Superior Performance to Myocardial Perfusion Imaging to Rule Out Obstructive Coronary Artery Disease

November 1, 2011
Solta and Medicis Announce Close of Agreement For LipoSonix

October 10, 2011
Longitude Capital Named the Top Performer in the Colorado PERA Venture Portfolio

October 10, 2011
James Tobin, Former CEO of Boston Scientific, Joins Aptus Board of Directors

September 26, 2011
Amarin Announces NDA Submission for AMR101 to Treat Patients With Very High Triglycerides

September 19, 2011
CardioDx Appoints Andrew Guggenhime as Chief Financial Officer and Mark Monane, M.D., as Chief Medical Officer

September 19, 2011
Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc

September 13, 2011
Medicis and Solta Announce Agreement for LipoSonix

September 1, 2011
Amarin Announces Successful MARINE Phase 3 Clinical Trial Results

August 10, 2011
Amarin Announces Agreement on Special Protocol Assessment for AMR101 Outcomes Study

July 12, 2011
Civitas Therapeutics secures $5M in financing

July 12, 2011
Barry M. Straube, M.D., Former Medicare Official and Leader of Major Quality and Policy Initiatives in Nephrology, Joins NxStage Board of Directors

June 17, 2011
NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the YearŽ 2011 New England Award Winner

June 30, 2011
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome

June 6, 2011
Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx in Directing Chemotherapy in Gynecologic Cancers

June 4, 2011
Corcept Therapeutics Announces Detailed Findings from Phase 3 Study

May 23, 2011
Aptus Endosystems Receives CE Mark for EndoStapling System

May 11, 2011
CardioDx Completes $60 Million in Equity Financing

May 6, 2011
Solta Medical Announces FDA 510(k) Clearance for NEW Clear + Brilliant Technology

April 30, 2011
PixelOptics Launches emPower!

April 18, 2011
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints

April 18, 2011
Precision Therapeutics Partners with Med Biogene to Commercialize LungExpress DX

April 7, 2011
PixelOptics Closes $45 Million Financing

April 7, 2011
Precision Therapeutics Announces New Tumor Profiling Product

April 5, 2011
New Multi-center Trial Results Demonstrate Ability of the CardioDx Corus CAD to Identify Obstructive Coronary Artery Disease and Add Independent Information to Coronary Calcium Scoring by CT Angiography

March 7, 2011
CardioDx Raises $40 Million

February 16, 2011
Fox Business Profiles PixelOptics' High Tech Eyeglasses

February 12, 2011
The New York Times Article on PixelOptics: Have You Charged Your Eyeglasses Today?

February 3, 2011
Solta Medical Introduces Two New Products at The American Academy of Dermatology

January 26, 2011
Corcept Therapeutics Announces Closing of $44.9 Million Underwritten Public Offering of Common Stock

January 19, 2011
Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx in Cancer Treatment Options

January 18, 2011
PixelOptics' emPower! Featured on "Live! With Regis and Kelly"

January 11, 2011
Amarin Announces Successful Completion of Offering of American Depositary Shares

January 11, 2011
Corcept Therapeutics Announces Key Secondary Endpoint Was Met in Phase 3 Study of CORLUX for Cushing's Syndrome

January 10, 2011
emPower! Electronic Focusing Eyeglasses Receives International Recognition at the 2011 Consumer Electronics Show

January 10, 2011
Civitas Therapeutics Secures $20 Million Series A Financing

© 2015 Longitude Capital Management Co., LLC. All rights reserved.